financetom
Business
financetom
/
Business
/
Liberty Energy Q4 Adjusted Earnings, Revenue Drop
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Liberty Energy Q4 Adjusted Earnings, Revenue Drop
Jan 29, 2025 3:10 PM

05:32 PM EST, 01/29/2025 (MT Newswires) -- Liberty Energy (LBRT) reported Q4 adjusted earnings late Wednesday of $0.10 per diluted share, down from $0.54 a year earlier.

Analysts surveyed by FactSet expected $0.11.

Revenue for the quarter ended Dec. 31 was $943.6 million, down from $1.08 billion a year earlier.

Analysts surveyed by Capital IQ expected $982.3 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Microsoft Unusual Options Activity For October 22
Microsoft Unusual Options Activity For October 22
Oct 22, 2024
Deep-pocketed investors have adopted a bullish approach towards Microsoft ( MSFT ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSFT usually suggests something big is about to happen. We gleaned this information from...
Walmart to deliver prescription medications as soon as 30 minutes
Walmart to deliver prescription medications as soon as 30 minutes
Oct 22, 2024
(Reuters) - Walmart ( WMT ) said on Tuesday it will now deliver prescription medicines and medication refills as a single order along with groceries and other items as soon as 30 minutes, as part of its new express delivery option. The retail bellwether's latest move comes a couple of weeks after technology giant Amazon.com ( AMZN ) announced its...
Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease
Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease
Oct 22, 2024
09:52 AM EDT, 10/22/2024 (MT Newswires) -- Ocugen ( OCGN ) said Tuesday that the Data and Safety Monitoring Board for its phase 1/2 clinical trial of CU410ST to treat Stargardt disease has approved enrollment for the trial's second phase. Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss. The biotech firm also said there...
J.M. Smucker to Sell Voortman Brand to Second Nature for $305 Million
J.M. Smucker to Sell Voortman Brand to Second Nature for $305 Million
Oct 22, 2024
09:48 AM EDT, 10/22/2024 (MT Newswires) -- J.M. Smucker (SJM) said Tuesday that it has agreed to sell its Voortman cookie brand to Second Nature Brands for $305 million in cash. The deal, expected to be completed in fiscal Q3, includes Voortman trademarks and a leased manufacturing facility of the company in Ontario, Canada, with around 300 employees transitioning, Smucker...
Copyright 2023-2026 - www.financetom.com All Rights Reserved